Enveric Biosciences Showcases EB-003 Development at EBPS Workshop

Enveric Biosciences, a biotechnology company specializing in the development of innovative neuroplastogenic small-molecule therapeutics for treating mental health disorders such as depression, anxiety, and addiction, has announced a significant advancement in its research efforts. The company has identified EB-003 as its leading development candidate. Preclinical data suggests that EB-003 exhibits substantial anxiolytic and anti-depressant properties without causing hallucinations, a significant improvement compared to other analogs of N,N-Dimethyltryptamine (DMT). The research findings were presented by Dr. Peter Facchini, the Chief Innovation Officer of Enveric, at the European Behavioral Pharmacology Society Biennial Workshop in Banff, Alberta, Canada, on September 26, 2024.

The presentation, titled "Semi-systematic series of DMT analogs for exploring relationships between hallucination, neuroplastigenicity, and positive behavioral outcomes in mice," detailed the methodology employed by Enveric to choose EB-003 from a series of 3D-designed analogs. The selection was based on behavioral outcomes observed in mouse models for anxiety and depression. Critical response measures in mice were highlighted, including head twitch response (HTR), which serves as a behavioral proxy in rodents for human hallucinogenic effects, as well as results from marble burying and sucrose preference tests, commonly used models for anxiety and depression, respectively. These findings indicate beneficial neuroplastogenic responses that are non-hallucinogenic in animal models.

Dr. Facchini expressed his pride in presenting the team's latest findings on EB-003 to the research community, emphasizing the importance of the European Behavioral Pharmacology Society's Biennial Workshop as a platform for advancing pharmacology-based interventions for substance use and related mental health disorders. He looked forward to building on this work and advancing EB-003 to clinical trials.

In recent developments, Enveric has confirmed the oral bioavailability of EB-003 through preclinical data, demonstrating its ability to achieve brain exposure at therapeutically relevant levels. The company anticipates filing an Investigational New Drug (IND) application for EB-003 by the third quarter of 2025, with plans to commence clinical development by the end of that year.

Enveric Biosciences, listed on NASDAQ under the ticker ENVB, is dedicated to creating novel neuroplastogenic small-molecule therapeutics aimed at treating depression, anxiety, and addiction disorders. Utilizing its proprietary discovery and development platform, Psybrary™, Enveric has developed a substantial intellectual property portfolio of new chemical entities for specific mental health conditions. EB-003, Enveric’s flagship program, represents a pioneering approach to addressing challenging mental health disorders by promoting neuroplasticity without inducing hallucinations. Furthermore, Enveric is developing EB-002, a next-generation synthetic prodrug of psilocin, which is under investigation for its potential use in treating psychiatric disorders.

Enveric Biosciences operates from its headquarters in Naples, Florida, with additional offices in Cambridge, Massachusetts, and Calgary, Alberta, Canada.